Cost-effectiveness and public health impact of RTS,S/AS01_E malaria vaccine in Malawi, using a Markov static model

Medicine & Life Sciences

• RTS,S-AS01E vaccine 100%
• Malaria Vaccines 62%
• Malawi 58%
• Cost-Benefit Analysis 39%
• Vaccines 34%
• Public Health 32%
• Malaria 27%
• Costs and Cost Analysis 23%
• Immunization Programs 18%
• Quality-Adjusted Life Years 16%
• RTS,S-AS01 vaccine 15%
• Appointments and Schedules 12%
• Gross Domestic Product 10%
• Ghana 9%
• Kenya 8%
• Antimalarials 8%
• Health Care Costs 6%
• Health Personnel 6%
• Vaccination 6%
• Parturition 5%
• Health 3%
• Child 3%

Chemical Compounds

• Dose 34%
• GDP 28%
• Antimalarial 27%
• Indicator 19%